Marshall Wace LLP Buys Shares of 13,800 Alumis Inc. (NASDAQ:ALMS)

Marshall Wace LLP purchased a new position in shares of Alumis Inc. (NASDAQ:ALMS) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 13,800 shares of the company’s stock, valued at approximately $108,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Geode Capital Management LLC acquired a new position in shares of Alumis during the 3rd quarter worth approximately $3,266,000. Norges Bank purchased a new stake in Alumis in the 4th quarter valued at about $1,606,000. Towerview LLC lifted its position in Alumis by 9.2% in the fourth quarter. Towerview LLC now owns 415,000 shares of the company’s stock valued at $3,262,000 after buying an additional 35,000 shares during the last quarter. Barclays PLC purchased a new position in Alumis during the third quarter worth about $197,000. Finally, Mariner LLC acquired a new stake in shares of Alumis during the fourth quarter valued at about $142,000.

Insider Buying and Selling

In other news, major shareholder Foresite Labs, Llc bought 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 6th. The stock was purchased at an average cost of $4.34 per share, with a total value of $86,800.00. Following the transaction, the insider now directly owns 4,247,670 shares in the company, valued at $18,434,887.80. This trade represents a 0.47 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Martin Babler purchased 15,650 shares of the business’s stock in a transaction on Tuesday, April 1st. The shares were purchased at an average cost of $6.44 per share, for a total transaction of $100,786.00. Following the transaction, the chief executive officer now owns 106,454 shares of the company’s stock, valued at $685,563.76. This trade represents a 17.23 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 397,044 shares of company stock worth $1,891,895 over the last 90 days.

Alumis Stock Down 1.1 %

Shares of NASDAQ ALMS opened at $4.35 on Wednesday. The business has a 50-day moving average of $5.40 and a two-hundred day moving average of $7.34. Alumis Inc. has a 1 year low of $3.18 and a 1 year high of $13.53.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ALMS. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price objective on shares of Alumis in a research report on Wednesday, April 30th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a report on Thursday, March 20th. Finally, Oppenheimer assumed coverage on Alumis in a research note on Thursday, January 30th. They set an “outperform” rating and a $32.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $25.86.

Alumis Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.